CANC vs IBBQ

CANCDTema Oncology ETF

IBBQAInvesco Nasdaq Biotechnology ETF

In short

CANC Most biotech funds buy the whole lab. CANC buys the cancer wing: an actively managed book of roughly 60 companies, with at least 80% of assets in firms that earn half their revenue or more from oncology.

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

Stated mandate

CANC The Fund seeks long-term growth. Its principal strategy invests at least 80% of net assets in publicly listed companies deriving at least 50% of revenue from oncology.

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

Why people hold it

• CANC The 50%-of-revenue test is the whole point. It screens for companies where cancer is the business, not a side project, then builds roughly 60 names around that.
• No oncology index to hug. A stock-picking team sets the portfolio, and the fund reports its results against the S&P 500 Total Return Index.stockanalysis.com
• Running since 2023, with a global mandate: the book can reach across US and European cancer franchises rather than stopping at the US border.stockanalysis.com

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

Worth knowing

• CANC Costs 0.75% net of a waiver through June 28, 2027, versus 0.99% gross, and above the category median. Index peers IBBQ (0.19%) and XBI (0.35%) ask less.
• A small fund that trades thinly, so spreads can be wider and order size matters more than with the largest biotech baskets.
• Concentration cuts both ways: trial readouts, pricing policy and regulatory decisions in one disease area move this book. Distributions come annually or semiannually.

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

Full CANC profile⁠

Full IBBQ profile⁠